Compound Planning Inc. Invests $483,000 in Moderna, Inc. $MRNA

Compound Planning Inc. purchased a new position in Moderna, Inc. (NASDAQ:MRNA) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 9,517 shares of the company’s stock, valued at approximately $483,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in MRNA. MUFG Securities EMEA plc bought a new position in Moderna during the 2nd quarter worth $28,000. Flagship Harbor Advisors LLC bought a new stake in Moderna in the fourth quarter valued at $31,000. Canton Hathaway LLC bought a new stake in Moderna in the first quarter valued at $31,000. Cromwell Holdings LLC boosted its holdings in shares of Moderna by 39.7% during the fourth quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock valued at $35,000 after acquiring an additional 341 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of Moderna by 148.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock valued at $37,000 after acquiring an additional 801 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Buying and Selling

In other Moderna news, Director Noubar Afeyan sold 9,263 shares of the firm’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $46.84, for a total value of $433,878.92. Following the completion of the transaction, the director directly owned 3,924 shares in the company, valued at $183,800.16. This trade represents a 70.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Abbas Hussain sold 5,682 shares of Moderna stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $46.63, for a total transaction of $264,951.66. Following the completion of the transaction, the director directly owned 12,066 shares in the company, valued at approximately $562,637.58. This trade represents a 32.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 125,088 shares of company stock worth $6,193,713 in the last quarter. 10.80% of the stock is currently owned by corporate insiders.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $54.49 on Thursday. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $85.60. The stock has a market cap of $21.62 billion, a price-to-earnings ratio of -6.69 and a beta of 0.94. The stock’s 50 day moving average price is $59.00 and its 200 day moving average price is $52.33. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.41 and a quick ratio of 2.35.

Moderna (NASDAQ:MRNA) last released its earnings results on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The firm had revenue of $389.00 million for the quarter, compared to analyst estimates of $236.37 million. During the same period in the previous year, the firm earned ($2.52) earnings per share. Moderna’s revenue was up 260.2% on a year-over-year basis. Equities research analysts anticipate that Moderna, Inc. will post -6.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Barclays upped their price target on shares of Moderna from $25.00 to $48.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 2nd. Jefferies Financial Group reissued a “hold” rating on shares of Moderna in a research note on Thursday, June 18th. Royal Bank Of Canada upped their target price on shares of Moderna from $38.00 to $45.00 and gave the stock a “sector perform” rating in a research report on Tuesday, July 7th. Piper Sandler raised their price target on shares of Moderna from $69.00 to $77.00 and gave the company an “overweight” rating in a research note on Friday, June 26th. Finally, The Goldman Sachs Group lifted their price target on Moderna from $49.00 to $67.00 and gave the company a “neutral” rating in a report on Tuesday, July 21st. Two research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and five have issued a Sell rating to the company. According to data from MarketBeat.com, Moderna has a consensus rating of “Reduce” and a consensus target price of $40.00.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.